ANNX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 106974 min ago

@ $5.26

Wydano: 14 vas. 2024 @ 21:48

Zwrot: -10.56%

Poprzedni sygnał: vas. 14 - 16:31

Poprzedni sygnał: Sprzedaż

Zwrot: 2.24 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Dzisiejszy wolumen	1.42M
Średni wolumen	1.65M
Kapitalizacja rynkowa	493.90M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $-0.440 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.66
ATR14	$0.00900 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock
2024-02-16	Artis Dean Richard	Buy	160 000	Stock Option (Right to Buy)

INSIDER POWER
80.77
Last 94 transactions
Buy: 9 088 380 \| Sell: 879 119

Wolumen Korelacja

Długi: -0.30 (neutral)

Krótki: -0.61 (weak negative)

Signal:(41.293) Neutral

Annexon, Inc. Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.934
GTHX	0.93
STKL	0.913
NUTX	0.91
EYE	0.91
DXCM	0.91
SDG	0.909
EAR	0.908
SVOK	0.907
RRGB	0.906

10 Najbardziej negatywne korelacje
HDSN	-0.916
LCA	-0.9
MDWT	-0.896
NVCN	-0.89
SENEA	-0.885
OHAA	-0.882
HNRG	-0.879
ROKU	-0.878
IGTA	-0.877
FCBP	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Annexon, Inc. Korelacja - Waluta/Towar

-0.16
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.35
( neutral )

Annexon, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2023
Przychody:	$0
Zysk brutto:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2022
Przychody:	$0
Zysk brutto:	$-3.31M (0.00 %)
EPS:	$-2.53

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-7.68

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.